Evaluation of new medication for heart failure.

What we are studying

The purpose of this research study is to test if study drug twice a day, compared to 160 mg of valsartan twice a day, is safe and effective in reducing the complications of heart failure, such as hospitalization for heart failure and death from cardiovascular causes.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 55+

Eligibility Criteria

  • Diagnosed with heart failure
  • Currently on a fluid pill
  • With no diagnosis of coronary artery disease.

What is involved

  • 8-10 visits over the first year
  • Visit or phone call every 3 months there after. May be in the study from 24-57 months.


Patients will be compensated for their time and travel.

Contact Information

Study Coordinator
Sarah Oliver
Principal Investigator
Dr. Dalane W. Kitzman

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.